Altogether, results shown in Figure 1 indicate that oral ABA, administered either before or after onset of hyperglycemia in a multiple low-dose STZ protocol of diabetes induction, improved the glycemia profile, the response to a glucose load, and the effect of low-dose insulin. The gene discussed is INS; the disease is diabetes mellitus.